BACKGROUND: Activated platelets release serotonin that binds 5-HT2B receptor on fibroblasts leading to fibroblast activation. Clopidogrel, an inhibitor of ADP-dependent platelet activation prevents fibrosis in animal models of systemic sclerosis (SSc). We aimed at assessing whether i) ADP-dependent platelet activation is increased in patients with SSc compared to healthy subjects and patients with rheumatoid arthritis (RA) and ii) whether clopidogrel can effectively suppress ADP-dependent activation, reduce circulating serotonin levels and hence, favorably affect fibrosis or vasculopathy in patients with systemic sclerosis. METHODS: Thirteen patients with SSc were recruited. Platelet activation was assessed by aggregometry prior to and following 14 days of clopidogrel treatment. At the same time points serotonin and soluble vascular cell adhesion molecule 1 (s-VCAM1), a marker of endothelial dysfunction, were measured. RESULTS: ADP-dependent platelet activation was similar between patients with SSc (nâ=â13), patients with RA (nâ=â28) and healthy subjects (nâ=â22) (meanâ±âSEM AU*min: 392.1â±â58.4, 535.5â±â61.33 and 570.9â±â42.9 in patients with SSc, patients with RA and healthy subjects respectively, pâ=â0.14). Clopidogrel treatment significantly reduced platelet activation in patients with SSc (meanâ±âSEM AU*min: 392.1â±â58.4 vs 163.8â±â51.7, pâ=â0.014). Clopidogrel treatment did not affect serotonin levels but led to a significant increase in s-VCAM1 (pâ=â0.03). Three patients developed new digital ulcers during the study. The potential association of the study drug with the development of new digital ulcers led to early termination of the study. CONCLUSION: Clopidogrel may worsen markers of endothelial function and associate with development of new digital ulcers in patients with SSc. CLINICAL TRIAL REGISTRATION: ISRCTN63206606 . Registered 02/Dec/2014.
Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.
氯吡格雷治疗可能与系统性硬化症患者内皮功能恶化和新发指端溃疡有关:一项开放标签概念验证研究的结果
阅读:16
作者:Ntelis Konstantinos, Gkizas Vasileios, Filippopoulou Alexandra, Davlouros Periclis, Alexopoulos Dimitrios, Andonopoulos Andrew P, Daoussis Dimitrios
| 期刊: | BMC Musculoskeletal Disorders | 影响因子: | 2.400 |
| 时间: | 2016 | 起止号: | 2016 May 17; 17:213 |
| doi: | 10.1186/s12891-016-1072-1 | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
